Schrödinger, Inc. (NASDAQ:SDGR) Shares Sold by Capital Impact Advisors LLC

Capital Impact Advisors LLC decreased its holdings in shares of Schrödinger, Inc. (NASDAQ:SDGR) by 16.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,827 shares of the company’s stock after selling 2,593 shares during the quarter. Capital Impact Advisors LLC’s holdings in Schrödinger were worth $248,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Texas Permanent School Fund Corp lifted its position in Schrödinger by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 47,869 shares of the company’s stock valued at $1,292,000 after purchasing an additional 626 shares during the last quarter. Louisiana State Employees Retirement System boosted its position in shares of Schrödinger by 2.6% during the second quarter. Louisiana State Employees Retirement System now owns 27,800 shares of the company’s stock worth $538,000 after buying an additional 700 shares during the period. GAMMA Investing LLC grew its holdings in Schrödinger by 49.5% in the 2nd quarter. GAMMA Investing LLC now owns 2,124 shares of the company’s stock worth $41,000 after buying an additional 703 shares in the last quarter. ProShare Advisors LLC increased its position in Schrödinger by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 10,987 shares of the company’s stock valued at $297,000 after acquiring an additional 753 shares during the period. Finally, Illinois Municipal Retirement Fund raised its stake in Schrödinger by 2.7% during the 1st quarter. Illinois Municipal Retirement Fund now owns 32,043 shares of the company’s stock valued at $865,000 after acquiring an additional 831 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Schrödinger Stock Performance

Schrödinger stock opened at $18.74 on Monday. Schrödinger, Inc. has a 52 week low of $18.02 and a 52 week high of $38.00. The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of -9.97 and a beta of 1.51. The company has a 50 day moving average price of $20.36 and a 200 day moving average price of $22.16.

Schrödinger (NASDAQ:SDGR) last issued its quarterly earnings results on Wednesday, July 31st. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.11. The business had revenue of $47.33 million for the quarter, compared to the consensus estimate of $40.19 million. Schrödinger had a negative return on equity of 38.38% and a negative net margin of 100.42%. Equities analysts forecast that Schrödinger, Inc. will post -2.19 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on SDGR shares. Leerink Partners began coverage on shares of Schrödinger in a research report on Tuesday, July 2nd. They set an “outperform” rating and a $29.00 price target on the stock. Morgan Stanley cut their target price on Schrödinger from $43.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 21st. Leerink Partnrs upgraded Schrödinger to a “strong-buy” rating in a research report on Tuesday, July 2nd. Finally, KeyCorp cut their price objective on Schrödinger from $30.00 to $25.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $33.44.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.